Accuray (ARAY)
(Delayed Data from NSDQ)
$1.77 USD
+0.20 (12.74%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.78 +0.01 (0.56%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.77 USD
+0.20 (12.74%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.78 +0.01 (0.56%) 7:58 PM ET
4-Sell of 5 4
B Value C Growth F Momentum C VGM
Zacks News
AMN Healthcare (AMN) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) Q4 results gain from core Nurse and Allied Solutions units.
LabCorp's (LH) Q4 Earnings Beat Estimates, Margins Rise
by Zacks Equity Research
LabCorp (LH) registered year-over-year growth in operating segments in Q4.
Ares Management (ARES) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Ares Management (ARES) delivered earnings and revenue surprises of 34.00% and 14.03%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Accuray, MagnaChip Semiconductor, Rite Aid, Vericel and RGC Resources
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Accuray, MagnaChip Semiconductor, Rite Aid, Vericel and RGC Resources
CVS Health (CVS) Q4 Earnings Top Estimates, Margins Improve
by Zacks Equity Research
CVS Health (CVS) registers strong growth in Pharmacy Services, benefiting from the upside in specialty services.
Exact Sciences (EXAS) Q4 Earnings and Revenues Rise Y/Y
by Zacks Equity Research
Exact Sciences' (EXAS) fourth-quarter 2019 results reflect strong segmental performances.
Virus or No Virus, Investing Case in US Stocks Looks Solid!
by Tirthankar Chakraborty
U.S. stocks are heavily exposed to the domestic economy where data continues to improve. And even if skeptics worry about the virus outbreak, developed markets are more stable than emerging markets during chaotic times.
Radware (RDWR) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Radware (RDWR) delivered earnings and revenue surprises of -4.17% and -0.22%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Luminex (LMNX) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Luminex's (LMNX) fourth-quarter earnings benefit from higher revenues and solid performance across System Sales, Service and Other Revenues. However, gross margin contraction remains a woe.
DaVita (DVA) Earnings Beat Estimates in Q4, Revenues Miss
by Zacks Equity Research
DaVita (DVA) gains from dialysis services in the United States in Q4.
STERIS (STE) Surpasses Q3 Earnings Estimates, Ups FY20 View
by Zacks Equity Research
STERIS' (STE) third-quarter fiscal 2020 results reflect strong segmental performances.
Myriad Genetics (MYGN) Misses Q2 Earnings & Revenue Estimates
by Zacks Equity Research
Myriad Genetics (MYGN) reports decline in Hereditary Cancer, GeneSight, Vectra and Prenatal revenues in Q2.
Omnicell (OMCL) Lags Q4 Earnings Estimates, Beats on Revenues
by Zacks Equity Research
Omnicell (OMCL) fourth-quarter 2019 results reflect strong segmental performances.
Pacific Biosciences (PACB) Reports Break-Even Earnings in Q4
by Zacks Equity Research
Pacific Biosciences (PACB) expects softness in first-quarter consumable sales.
Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Surmodics' (SRDX) fiscal first-quarter earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.
Cardinal Health (CAH) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Cardinal Health (CAH) fiscal second-quarter results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.
Becton, Dickinson (BDX) Q1 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Becton, Dickinson (BDX) sees softness in BD Medical unit, slashes FY20 view.
ABIOMED (ABMD) Earnings Beat Estimates in Q3, Revenues Miss
by Zacks Equity Research
Flagship Impella drives ABIOMED's (ABMD) fiscal third-quarter results; FY20 revenue guidance slashed.
Cardiovascular Systems (CSII) Loss Wider Than Estimates in Q2
by Zacks Equity Research
We are upbeat about Cardiovascular Systems' (CSII) year-over-year uptick in global Coronary and peripheral device revenues during Q2.
Haemonetics (HAE) Q3 Earnings & Revenues Beat, Margins Expand
by Zacks Equity Research
Haemonetics (HAE) fiscal third-quarter 2020 results reflect strong performances in Plasma and Hospital segments.
Boston Scientific (BSX) Q4 Earnings Beat, Margins Decline
by Zacks Equity Research
Boston Scientific (BSX) is steadily investing in new technologies as well as the global markets, reflecting its uptick in sales across most geographies in Q4.
QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
QIAGEN (QGEN) registered revenue growth across majority of its geographies and each of its operating segments in Q4
Cerner (CERN) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Cerner (CERN) fourth-quarter results benefit from higher revenues, gains in Licensed software, Technology resale, Professional and Managed services units, and international revenue growth.
Zimmer Biomet (ZBH) Q4 Earnings Top Estimates, Margins Grow
by Zacks Equity Research
Zimmer Biomet (ZBH) benefits from strong sales growth across all geographies as well as segmental strengths at CER.
Phibro (PAHC) Q2 Earnings Top Estimates, Revenues Fall Y/Y
by Zacks Equity Research
Phibro (PAHC) witnessed revenue decline in two of its core segments and contraction in operating margin in Q2.